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tions, 3) low levels of platelets (<100 
× 109/L) and 4) increased capillary 
permeability (5). Our patient fulﬁ  lled 
all 4 criteria. Few cases of reported 
DHF fulﬁ  ll criterion 3 due to the short 
duration of severe thrombocytopenia 
in mild clinical forms (8). Increased 
vascular permeability was shown in 
our patient by the peritoneal and bilat-
eral pleural effusions.
The probability of diagnosing 
dengue fever in Europe increases with 
travel to dengue-endemic areas, in 
view of the increase of DHF numbers 
(2006–2007) and several outbreaks 
around the world, even during the non-
dengue season (9). Frequent travelers 
are more at risk for DHF. In a recent 
European publication, 17% of patients 
with imported dengue fever exhibited 
a secondary immune response, thus 
having a higher risk of developing 
DHF in the future (6). Serologic tests 
conﬁ   rm dengue infection only if a 
4-fold increase in titers in consecutive 
serum samples occurs, as in our case.
In dengue-endemic areas, despite 
the higher disease incidence, many 
cases still fail to meet WHO criteria 
(9). A comprehensive revision of den-
gue and DHF series (8) shows differ-
ences in applying WHO criteria for di-
agnosis, and sometimes the correlation 
was poor between criteria-fulﬁ  lling 
cases and severity of disease. Some 
reports (6,8) suggest that WHO cri-
teria should be reviewed and perhaps 
new parameters should be established 
to deﬁ  ne severe dengue disease.
Although our patient was not in-
fected in Europe, lessons from the 
recently described chikungunya out-
break in Italy indicate the possibility of 
new arbovirus outbreaks in previously 
non–disease-endemic areas due to the 
increasingly established presence of 
vectors like Ae. albopictus (10).
Dengue virus infection should 
therefore be considered in the differ-
ential diagnosis of fever in returning 
travelers. DHF diagnosis, although 
unusual, could become more frequent 
in the future.
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Mycobacterium 
setense Infection in 
Humans
To the Editor: A 66-year-old man 
had a bone graft for treatment of an 
oroantral ﬁ  stula in March 2007 in Mar-
seille, France. The surgery consisted of 
a bilateral maxillary sinus ﬁ  lling with 
a parietal osseous graft to close the ﬁ  s-
tula (position 24–25). Painful edema of 
the hemiface and mild fever developed 
in the patient in July 2007. Computed 
tomography showed areas of hypoden-
sity in the osseous graft in the left max-
illary sinus consistent with osteolysis. 
Microscopic examination of a bone 
biopsy specimen after gram staining 
did not reveal any organisms but this 
specimen did grow Enterobacter cloa-
cae  and colonies of a gram-positive 
bacillus after a 2-day inoculation on 
5% blood agar incubated at 37°C in 
an atmosphere of 5% CO2. Tentative 
identiﬁ  cation of this catalase-positive, 
oxidase-negative gram-positive rod 
(isolate 74023791) by an API Coryne 
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strip (API bioMérieux, La Balme-les 
Grottes, France) remained inconclu-
sive. Isolate 74023791 exhibited acid 
fastness and was further identiﬁ  ed by 
comparing its 16S rDNA (1) and heat 
shock protein 65 (hsp65) (2) sequences 
with those in the GenBank database and 
its RNA polymerase subunit B (rpoB) 
sequences (3) with those of Mycobac-
terium spp. in our local rpoB database. 
Antimicrobial susceptibility testing
using E-test  (AB Biodisk, Bruz, 
France) indicated that isolate 
74023791 was susceptible to cipro-
ﬂ   oxacin with an MIC of 0.047 μg/
mL and resistant to amoxicillin (MIC 
>256 μg/mL), ceftriaxone (MIC >256 
μg/mL), erythromycin (MIC >256 μg/
mL), clarithromycin (MIC >256 μg/
mL), and rifampin (MIC >32 μg/mL). 
Disk testing and reference broth dilu-
tion method (4) showed that isolate 
74023791 was susceptible to imipen-
em after a 3-day incubation. However, 
E-test showed heterogeneous resis-
tance with colonies exhibiting an MIC 
>256 μg/mL. The same observations 
were made for Mycobacterium setense 
type strain CIP109395T (Collection 
de l’Institut Pasteur, Paris, France) (5). 
Daily treatment with 2 g imipenem and 
1.5 g ciproﬂ  oxacin was prescribed for 
1 month before the imipenem E-test 
and broth dilution results were avail-
able, and was followed by 1.5 g/day 
ciproﬂ  oxacin for 3 months, resulting 
in a favorable clinical and radiologic 
evaluation at 5-month follow-up. 
Phylogenetic analyses indicated 
that isolate 74023791 belonged to 
the  M. fortuitum group, along with 
M. porcinum and M. conception-
ense, and was most closely related 
to M. setense, a recently described 
species of this group (5) (Figure). 
Isolate 74023791 shared 100% 16S 
rDNA (GenBank accession no. 
EU371507), 99.5% hsp65 (accession 
no. EU371508), and 99.0% rpoB (ac-
cession no. EU371509) sequence sim-
ilarity with M. setense (accession nos. 
EF138818 and EU371504, EF138819 
and EU371505, and EF414447 and 
EU371506, respectively). Because the 
99% rpoB sequence similarity of the 
patient’s isolate was above the 97% 
rpoB sequence similarity cut-off value 
used to identify rapidly growing my-
cobacteria (3), isolate 74023791 was 
therefore identiﬁ  ed as M. setense. 
M. setense, in association with an 
E. cloacae strain susceptible to anti-
microbial drug therapy, was an agent 
of infection in our patient. It is note-
worthy that M. setense and the close-
ly-related species M. conceptionense 
were isolated from patients with post-
traumatic osteitis (5,6); M. porcinum 
was isolated from 7/46 cases of os-
teomyelitis and additional cases of 
postsurgical infection, respectively 
(7);  M. fortuitum osteomyelitis has 
also been reported (8). These data 
emphasize the role of M. fortuitum 
group organisms in posttraumatic and 
postsurgical osteitis. 
In a later interview, the patient 
disclosed that he rinsed his mouth 
with well water during the weeks after 
receiving the bone graft. We initially 
suspected that the water was the source 
of M. setense, as previously suspected 
for M. conceptionense (6) and reported 
for M. porcinum (7). However, neither 
M. setense nor M. setense DNA were 
detected in the well water in October 
2007. 
Initially,  M. setense was report-
ed to be susceptible to imipenem by 
the disk diffusion method, which is 
not the reference method (5). In this 
report, the disk and reference broth 
dilution methods showed that both 
clinical and reference M. setense 
strains were initially susceptible to 
imipenem but the E-test disclosed that 
both strains exhibited heterogeneous 
resistance to imipenem; colonies ex-
hibited an MIC >256 μg/mL. This 
result was unexpected because the 
E-test showed that related species M. 
fortuitum CIP104534T, M. concep-
tionense, CIP 108544T and M. porci-
num CIP105392T were susceptible to 
imipenem (6). Likewise, the modiﬁ  ed 
broth dilution method showed that the 
MIC for imipenem was <4 μg/ml for 
M. fortuitum ( 9). However, when a 
broth dilution method was used, the 
MIC for imipenem ranged from 0.5 
μg/mL to 8 μg/mL in 42 M. porcinum 
strains (7). Together, these data chal-
lenge the susceptibility to imipenem in 
organisms of the M. fortuitum group.   
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Figure. Phylogenetic position of isolate 74023791 and 16 rapidly growing Mycobacterium species based on A) 16S rDNA, B) partial 
RNA polymerase subunit B, and C) partial heat shock protein 65 sequences analyzed by using the neighbor-joining method and Kimura 
2-parameter distance correction model. The support of each branch, as determined from 1,000 bootstrap samples, is indicated by the 
value at each node when >80% (as a percentage). M. tuberculosis was used as the outgroup species. Scale bars represent differences 
in nucleotide sequences. LETTERS
M. setense is an emerging organ-
ism of the M. fortuitum group that must 
be added to the growing list of rapidly 
growing mycobacteria isolated from 
humans. The initial gram-positive rod 
appearance of M. setense may delay its 
accurate identiﬁ  cation. Determination 
of antimicrobial drug susceptibility 
needs to be conducted by the reference 
broth dilution method. Further reports 
are warranted to characterize the role 
of M. setense in infection.
This report was supported by Unité 
des Rickettsies CNRS IRD UMR 6236.  
Alexandre Toro,* 
Toidi Adekambi,† 
François Cheynet,‡ 
Pierre-Edouard Fournier,* 
and Michel Drancourt*
*Université de la Méditerranée, Marseille, 
France; †Centers for Disease Control and 
Prevention, Atlanta, Georgia, USA; and 
‡Assistance Publique Hôpitaux de Mar-
seille, Marseille, France  
References
  1.   Weisburg WG, Barns SM, Pelletier DA, 
Lane DJ. 16S ribosomal DNA ampliﬁ  ca-
tion for phylogenetic study. J Bacteriol. 
1991;173:697–703.
  2.   Ringuet H, Akoua-Kofﬁ   C, Honore S, Var-
nerot A, Vincent V, Berche P, et al. hsp65 
sequencing for identiﬁ   cation of rapidly 
growing mycobacteria. J Clin Microbiol. 
1999;37:852–7.
  3.   Adekambi  T,  Colson  P,  Drancourt  M. 
rpoB-based identiﬁ   cation of nonpig-
mented and late-pigmenting rapidly 
growing mycobacteria. J Clin Micro-
biol. 2003;41:5699–708. DOI: 10.1128/
JCM.41.12.5699-5708.2003
    4.   National Committee for Clinical Labo-
ratory Standards. Susceptibility testing 
of mycobacteria, Nocardiae and other 
aerobic actinomycetes: approved standard 
M24–A. Wayne (PA): The Committee; 
2003.
  5.   Lamy B, Marchandin H, Hamitouche K, 
Laurent F. Mycobacterium setense sp. 
nov., a Mycobacterium fortuitum–group 
organism isolated from a patient with soft 
tissue infection and osteitis. Int J Syst 
Evol Microbiol. 2008;58:486–90. DOI: 
10.1099/ijs.0.65222-0
  6.   Adekambi T, Stein A, Carvajal J, Raoult D, 
Drancourt M. Description of Mycobacte-
rium conceptionense sp. nov., a Mycobac-
terium fortuitum group organism isolated 
from a posttraumatic osteitis inﬂ  amma-
tion. J Clin Microbiol. 2006;44:1268–73. 
DOI: 10.1128/JCM.44.4.1268-1273.2006
    7.    Wallace RJ Jr, Brown-Elliott BA, Wil-
son RW, Mann L, Hall L, Zhang Y, et 
al. Clinical and laboratory features of 
Mycobacterium porcinum. J Clin Micro-
biol. 2004;42:5689–97. DOI: 10.1128/
JCM.42.12.5689-5697.2004
    8.   Tejan-Sie SA, Robin K, Avery SH, 
Mossad SB. Mycobacterium fortui-
tum osteomyelitis in a peripheral blood 
stem cell transplant recipient. Scand 
J Infect Dis. 2000;32:94–6. DOI: 
10.1080/00365540050164317
  9.   Lee SM, Kim J, Jeong J, Park YK, Bai 
GH, Lee EY, et al. Evaluation of the broth 
microdilution method using 2,3-diphenyl-
5-thienyl-(2)-tetrazolium chloride for rap-
idly growing mycobacteria susceptibility 
testing. J Korean Med Sci. 2007;22:784–
90.
Address for correspondence: Michel Drancourt, 
Unité des Rickettsies, Faculté de Médecine, 
Université de la Méditerranée, 27 Blvd Jean 
Moulin, 13385 Marseille CEDEX 5, France; 
email: michel.drancourt@medecine.univ-mrs.fr
Human Bocavirus 
in Tonsillar 
Lymphocytes
To the Editor: We read with great 
interest the recent report by Longtin 
and colleagues (1) describing human 
bocavirus (HBoV) infection among 
Canadian children with acute respi-
ratory tract illnesses (ARI). The au-
thors identiﬁ  ed HBoV by PCR in na-
sopharyngeal aspirates from 13.8% of 
young children hospitalized with ARI, 
an infection rate well within the range 
reported by other studies on children 
(2). However, these authors also de-
tected an unexpectedly high rate of 
HBoV for their control group (43%), 
>3 times the rate for ARI case-patients. 
In contrast, several similar studies did 
not detect HBoV in asymptomatic chil-
dren. Kesebir et al. detected HBoV in 
23 (5.2%) of 425 young children with 
ARI but in none of 96 children during 
routine well-child visits (3). Maggi 
et al. detected HBoV in 9 (4.5%) of 
200 infants with ARI but in none of 
30 healthy infants or 21 preadolescent 
healthy children without signs of ARI 
or history of asthma or wheezing (4). 
Finally, Allander et al. detected HBoV 
in 5 (19%) of 259 young children with 
acute expiratory wheezing but in none 
of 64 children who had not had respi-
ratory symptoms during the preceding 
4 weeks (5). In a recent study, we de-
tected HBoV by PCR in 44 (12%) of 
369 Thai children <4 years of age hos-
pitalized with pneumonia but in only 
2 (2%) of 85 asymptomatic age and 
temporally matched controls (6).
The inexplicably high rate of 
HBoV infection for patient controls 
reported by Longtin et al. (1) may re-
ﬂ  ect a unique feature of the children 
selected. The 100 controls were chil-
dren without concomitant respiratory 
symptoms or fever at admission who 
were hospitalized during the study pe-
riod for elective surgery, primarily of 
the ear, nose, and throat (71%). Most 
surgeries consisted of myringotomies, 
adenoidectomies, and tonsillectomies. 
The authors reported that these surger-
ies were more frequently performed 
on children found to be PCR positive 
for HBoV than on children negative 
for HBoV (84% vs. 61%). One possi-
ble explanation is that HBoV infection 
may directly induce inﬂ  ammation of 
tonsillar tissues or facilitate bacterial 
superinfection prompting surgical in-
tervention. Another possibility is that 
inﬂ   ammation of mucosal lymphoid 
tissues enhances HBoV replication by 
recruitment of immune cells permis-
sive for HBoV infection or by latent 
virus reactivation. Persistent infections 
and dependence on rapidly dividing 
cells are common features of the relat-
ed parvoviruses, for example, human 
erythrovirus B19 (7). The presence of 
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